MSInsight

MSInsight is a Paris-based diagnostics company focused on transforming cancer care through the precise detection of microsatellite instability (MSI). Its proprietary AI-powered software platform, MSIcare, analyzes next-generation sequencing (NGS) data to provide actionable insights for treatment selection, primarily for solid tumors like colorectal, endometrial, and gastric cancers. The company targets NGS laboratories, clinical practitioners, and the pharmaceutical industry, aiming to integrate its tool into standard oncology workflows to enable personalized medicine. Backed by academic founders and having won recognition from the France 2030 initiative, MSInsight is positioned in the growing market for companion diagnostics and biomarker-driven oncology.

MSIcare: An AI-powered bioinformatics software platform that analyzes NGS data (FASTQ/BAM files) from solid tumors and liquid biopsies to detect microsatellite instability (MSI). It is sequencing-agnostic and designed for pan-cancer analysis.

Competitors range from large, comprehensive genomic profiling companies (e.g., Foundation Medicine, Guardant Health) to diagnostic labs offering MSI testing via PCR/IHC, and other bioinformatics startups. MSInsight's differentiation lies in its specialized AI focus on MSI, pan-cancer/liquid biopsy capability, and platform-agnostic software model.